Capricor Therapeutics Investors Face Class Action Following Stock Collapse

The legal action concerns investors who purchased Capricor Therapeutics (NASDAQ: CAPR) securities between December 17, 2025, and July 26, 2026. The shift in market confidence occurred rapidly following the release of FDA documents on July 27, 2026, which indicated that the company's study failed to meet primary and secondary efficacy endpoints for its deramiocel treatment. Furthermore, the agency noted that the final statistical analysis plan had not been agreed upon prior to the study's unblinding.

Shares plummeted from a class-period high of $35.34 on April 21, 2026, to $4.19 by July 30, 2026. This decline was exacerbated by an advisory committee vote where members decided 9-3 that available evidence did not support the drug's efficacy for DMD-associated cardiomyopathy. Levi & Korsinsky, LLP, which is representing the class, alleges that the company failed to disclose that its final analysis plan was created only one day before unblinding, rendering the results exploratory rather than definitive. Investors seeking to participate as a lead plaintiff in the litigation must submit their information before the September 28, 2026, deadline.